Clinical trials: Adenocarcinoma of the Prostate
Prostate Cancer, Prostate Adenocarcinoma
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
- Trial name
- NCT05710380
- Testing
- Risk Map Decision Support System (DSS)., Magnetic Resonance Imaging (MRI), Magnetic Resonance Imaging (MRI) Guided Biopsy
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- University of Chicago
Prostate Cancer, Non-metastatic Prostate Cancer
PROState Pathway Embedded Comparative Trial
The proposal will explore a trial design called the cohort-multiple RCT (cmRCT) or as it has been recently coined, the Trials WithIn Cohorts (TWICS) design.
- Conditions
- Prostate Cancer, Non-metastatic Prostate Cancer, Metastatic Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- IP3-PROSPECT (NCT04400656)
- Where
- 3 sites in United Kingdom
- Volunteers
- 139 people
- Sponsor
- Imperial College London
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT02099864
- Testing
- Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
Phase II trial to study the effectiveness of combining paclitaxel and bryostatin 1 in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
- Trial name
- NCT00005028
- Testing
- bryostatin 1, paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of Maryland, Baltimore
Prostatic Neoplasms
Efficacy and Safety Study of Xyotax to Treat Prostate Cancer
The purpose of this study is to determine whether Xyotax, a conjugate of the taxane drug paclitaxel, is effective in the treatment of prostate cancer that is no longer responsive to hormone therapy.
- Trial name
- NCT00446836
- Testing
- Paclitaxel polyglumex (Xyotax)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The Methodist Hospital Research Institute
Genitourinary Cancers
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
SOGUG-PRINCIS is a retrospective (regarding patient inclusion) and prospective follow-up, epidemiological, non-interventional, non-blinded, non-randomized, multicenter, national observational study with drugs.
- Trial name
- SOGUG-PRINCIS (NCT06724159)
- Testing
- darolutamide, Nivolumab monotherapy, enfortumab vedotin
- Where
- 84 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Prostatic Neoplasms
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.
- Trial name
- NCT00040170
- Testing
- MVA-MUC1-IL2
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Transgene
Adenocarcinoma of the Prostate
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
The ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer compared to participants followed on active surveillance…
- Trial name
- ProVent (NCT03686683)
- Testing
- sipuleucel-T
- Where
- 56 sites in United States
- Volunteers
- 532 people
- Sponsor
- Dendreon
Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant
- Trial name
- BAT-RAD (NCT04704505)
- Testing
- radium-223, Bipolar Androgen Therapy (BAT)
- Where
- 2 sites in United States, Brazil
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Adenocarcinoma
Neoadjuvant Embolization and Cytoreduction in Prostate Cancer
The goal of this clinical trial is to find out whether prostate artery embolization (PAE) can help prevent or lessen urinary side effects caused by radiotherapy (RT) in people with prostate cancer, especially those who have…
- Trial name
- NCT07251829
- Testing
- Prostatic Artery Embolization
- Volunteers
- 35 people
- Sponsor
- Srinivas Raman
Adenocarcinoma of the Prostate
Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
The purpose of this research study is to determine if dose-escalated proton radiation therapy is a good way to treat high-risk prostate cancer.
- Trial name
- PR11 (NCT03624660)
- Testing
- HR-A, HR-B
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Florida
Prostate Adenocarcinoma
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features
Evaluation the ERG expression in prostatic acinar adenocarcinoma and its association with clinicopathological features.
- Trial name
- NCT04825691
- Testing
- Immunohistochemistry of prostate biopsy
- Volunteers
- 50 people
- Sponsor
- Assiut University
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Localized Prostate Cancer
Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer
The purpose of this study is to evaluate the safety and effectiveness of AD5-SGE-REIC/Dkk-3 in patients with localized prostate cancer.
- Trial name
- NCT01931046
- Testing
- Ad5-SGE-REIC/Dkk3
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Momotaro-Gene Inc.
Prostate Cancer
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have prostate…
- Trial name
- NCT00016393
- Testing
- ixabepilone
- Where
- 28 sites in United States
- Sponsor
- SWOG Cancer Research Network
Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
This phase II trial compares giving estrogen with an androgen receptor signaling inhibitor to standard of care luteinizing hormone-releasing hormone (LHRH) analogues with an androgen receptor signaling inhibitor for improving…
- Conditions
- Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT07466498
- Testing
- Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Stage IV Prostate Cancer, Bone Metastases
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate…
- Conditions
- Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
- Trial name
- NCT00019695
- Testing
- alendronate sodium, ketoconazole
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00242931
- Testing
- Nonmyeloablative stem cell conditioning regimen
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer, Prostate Adenocarcinoma
MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
1. The investigators hypothesize that increasing radiation dose to the functional MRI-defined lesion in the prostate bed will result in an improved initial complete response (reduction in prostate-specific antigen (PSA) to < 0.1…
- Trial name
- MAPS (NCT01411345)
- Testing
- Standard Salvage Radiation Treatment (SSRT), Mapped Tumor Salvage RT (MTSRT)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Miami
Prostate Cancer
Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer
RATIONALE: Diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging or DCE-MRI and diffusion-weighted imaging or DWI, may provide images of prostate cancer or any cancer that remains after biopsy.
- Trial name
- A6701QIBA (NCT01562223)
- Testing
- motexafin gadolinium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- American College of Radiology Imaging Network